Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for General Biologicals's ROE % or its related term are showing as below:
ROCO:4117'
s ROE % Range Over the Past 10 Years
Min: -56.64 Med: -36.33 Max: 106.56
Current: 106.56
During the past 13 years, General Biologicals's highest ROE % was 106.56%. The lowest was -56.64%. And the median was -36.33%.
ROCO:4117's ROE % is ranked better than 97.65% of 937
companies
in the Drug Manufacturers industry
Industry Median: 6.06
vs ROCO:4117: 106.56
General Biologicals (ROCO:4117) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
General Biologicals ROE % Related Terms
General Biologicals ROE % Historical Data
* Premium members only.
The historical data trend for General Biologicals's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, General Biologicals's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
General Biologicals ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, General Biologicals's ROE % distribution charts can be found below:
* The bar in red indicates where General Biologicals's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
General Biologicals (ROCO:4117) has a ROE % of 231.61% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on General Biologicals and its competitors. According to the industry distribution chart, General Biologicals ranks #22 out of 937 companies in the Drug Manufacturers industry, placing it in the top 2.3%.
Is General Biologicals' ROE % too high?
General Biologicals' current ROE % is 231.61%. The Drug Manufacturers industry median ROE % is 6.06. General Biologicals' value of 231.61% is 3721.9% above this industry median. Based on the distribution chart, General Biologicals ranks #22 out of 937 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, General Biologicals has a GF Score™ of 50/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does General Biologicals' ROE % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, General Biologicals ranks #22 out of 937 companies for ROE %. This places General Biologicals in the top 2% of its industry — outperforming the majority of peers. The industry median ROE % is 6.06. General Biologicals' value of 231.61% is 3721.9% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.06, based on 937 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. General Biologicals's current ROE % of 231.61% is 3721.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on General Biologicals and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. General Biologicals's current ROE % is 231.61%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is General Biologicals stock overvalued right now?
Based on GuruFocus' analysis, General Biologicals (ROCO:4117) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$14.06, compared to a current price of NT$10.40 — trading 26% below its estimated fair value. The current ROE % is 231.61% and 3721.9% above the Drug Manufacturers industry median of 6.06. General Biologicals' overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For General Biologicals (ROCO:4117), the current ROE % is 231.61% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is General Biologicals (ROCO:4117) Overvalued in 2026?
Based on GuruFocus' analysis, General Biologicals stock appears to be undervalued.
The current stock price of NT$10.40 is trading 26% below its estimated GF Value™ of NT$14.06.
GuruFocus considers General Biologicals to be Modestly Undervalued.
Key valuation signals for ROCO:4117:
ROE %: 231.61%
GF Value™: NT$14.06 vs. price of NT$10.40 (26% below fair value)
Industry Position: 3721.9% above the Drug Manufacturers median (#22 of 937)
No single metric tells the full story. See the ROCO:4117 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
General Biologicals Corp is a developer and manufacturer of vitro diagnostic devices in Taiwan. It offers research development, marketing and servicing of products and solutions for hospitals, medical laboratories, blood banks, and research and industry. Its products include Anti-HDV, HIV Ag-Ab COMB, Anti-HBs, and many others.
50GF Score
Get the complete analysis for ROCO:4117
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4117 has been successfully added to your 
